MARKET

LXRX

LXRX

Lexicon Pharmaceuticals Inc
NASDAQ
1.230
+0.050
+4.24%
After Hours: 1.230 0 0.00% 19:53 02/06 EST
OPEN
1.200
PREV CLOSE
1.180
HIGH
1.270
LOW
1.200
VOLUME
2.09M
TURNOVER
--
52 WEEK HIGH
1.830
52 WEEK LOW
0.2836
MARKET CAP
447.06M
P/E (TTM)
-6.4942
1D
5D
1M
3M
1Y
5Y
1D
LEXICON ANNOUNCES CLOSING OF APPROXIMATELY $94.6 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT
Reuters · 1d ago
Major Insider Makes Bold New Bet on Biotech Player
TipRanks · 3d ago
Lexicon Pharmaceuticals Bolsters Capital Through Equity Financing
TipRanks · 5d ago
Weekly Report: what happened at LXRX last week (0126-0130)?
Weekly Report · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer
Reuters · 01/30 18:38
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 01/30 17:05
Gold Tumbles Over 6%; Apple Posts Upbeat Earnings
Benzinga · 01/30 17:05
Midday Fly By: Warsh nominated for Fed chair, Apple reports Q1 beat
TipRanks · 01/30 17:01
More
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.

Webull offers Lexicon Pharmaceuticals Inc stock information, including NASDAQ: LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.